California false hellebore

Other Names

California corn lilyCalifornia helleboreCalifornian false helleboreColorado false helleboreCorn lilyCow cabbageFalse helleboreFalse skunk cabbageSkunk cabbageVeratrumVeratrum album var. californicumVeratrum californicumVeratrum californicum DurandVeratrum californicum var. californicumVeratrum californicum var. caudatumVeratrum caudatum var. tenuipetaloidesVeratrum eschscholtzii var. watsoniiVeratrum jonesiiVeratrum jonesii A.HellerVeratrum speciosumVeratrum speciosum Rydb.Veratrum tenuipetalumVeratrum tenuipetalum A.HellerWestern false helleboreWhite false helleboreWild corn

Synopsis

California False Hellebore (Veratrum californicum): A Comprehensive Reference

1. Identity and Botanical Description

1.1 Nomenclature and Taxonomy

The genus Veratrum consists of 17–45 species, most of which naturally occur in Asia, and all located exclusively in the Northern Hemisphere. These perennials have been classified as part of either the Liliaceae or the Melanthiaceae family, though wide variety within the genus has led to an absence of rigidly defined taxonomy. California false hellebore is formally designated Veratrum californicum Durand, first described in the Journal of the Academy of Natural Sciences of Philadelphia in 1855. In English, Veratrum species are known collectively as false hellebores, false helleborines, and corn lilies; however, Veratrum is not closely related to true hellebores, helleborines, maize, or lilies.

Two varieties are recognized: Veratrum californicum var. californicum and Veratrum californicum var. caudatum, the latter sometimes assigned its own species name Veratrum tenuipetalum. Common synonyms and vernacular names include California corn lily, corn lily, wild corn, cow cabbage, skunk cabbage, and western false hellebore.

1.2 Morphology and Habitat

California false hellebore is an erect herb and its stems reach 1–2.5 m in height and are roughly glabrous proximally and tomentose distally. Leaves are ovate (the uppermost lanceolate to lance-linear), 20–40 × 15–25 cm, reduced distally, and are tomentose-ciliate, with curly hairs on the lower surface. The plant grows as a single, unbranched stalk, flowering in cream-colored blooms at the top.

Primarily an alpine and subalpine plant, California false hellebore grows in dense stands near streams, in moist mountain meadows, and on damp hillsides at elevations between 6,000 and 11,000 feet. It is the largest native member of the lily family in its range; it is rhizomatous and inhabits moist meadows and woodlands from lowlands to subalpine zones.

1.3 Natural Forms and Preparations

Over 100 alkaloids have been identified from Veratrum, mostly from extraction of the root and rhizome, with several of the alkaloids demonstrating cancer suppression, induction of bradycardia, analgesia, and other effects. All parts of the plant are considered toxic, but the roots are reported to be 5–10 times more toxic than leaves. Historically, the plant's parts have been used in the following preparations:

Dried, powdered root — used as an insecticide, parasiticide, or topical application
Decoctions and infusions of the root/rhizome for oral or topical traditional medicinal use
Tinctures incorporated into ointments for external application
Ethanolic extracts of the root and rhizome, used in modern pharmacognostic and drug-discovery research

All parts of Veratrum plants have been used for the treatment of ailments including injuries, hypertension, and rheumatic pain since as far back as the 1600s. The plant is little, if at all, used in modern Western herbalism.

2. Traditional and Historical Use

2.1 Native American Ethnobotany

Western Native Americans — including the Blackfeet, Paiute, Shoshone, Thompson, and Washoe peoples — used this species as an antirheumatic, poison, contraceptive, and emetic, as well as a skin, respiratory, blood, cold, snakebite, throat, and toothache aid (D. E. Moerman 1986).

Although a very poisonous plant, California false hellebore was often employed medicinally by a number of Native North American Indian tribes who used it mainly as an external application to treat wounds. It also had quite a reputation as a contraceptive. A dose of one teaspoon of a decoction three times a day for three weeks is reported in some folkloric sources as a method said to ensure permanent sterility in women — though this represents a highly dangerous use given the plant's known toxicity, and no clinical evidence supports this application.

Native Americans were well aware of Veratrum's extreme toxicity and used the roots to poison arrows before combat. The roots, when dried and ground into powder, were also used as an insecticide. Western American Indian tribes have a long history of using these plants medicinally, and combined minute amounts of the winter-harvested root with Salvia dorii to potentiate the effects and reduce the herb's toxicity.

The dried and powdered root was used as an insecticide and a parasiticide.

2.2 Broader Ethnobotanical and Historical Context in Western Medicine

Veratrum plants have been remedies of popular medicine for hundreds of years. They were used against sorcery in the Middle Ages and later as emetics and as drugs for neuralgia. After the classical descriptions of their effects on the heart, Veratrum extracts and, thereafter, their purified alkaloids were proposed as therapeutic tools for arterial hypertension.

During the 1930s, Veratrum extracts were investigated in the treatment of high blood pressure in humans. While initial results were promising, many of the patients suffered side effects due to the narrow therapeutic index of these products. Protoveratrine was the preferred alkaloid for antihypertensive treatment in this era. These therapeutic uses were ultimately abandoned because of intolerable side effects, namely nausea and vomiting and profound hypotension.

Plants of the genus Veratrum have a long history of use in the folk remedies of many cultures, and the jervine family of alkaloids, which constitute a majority of Veratrum secondary metabolites, have been used for the treatment of hypertension and cardiac disease.

Veratrum plants are known both in Western herbalism and traditional Chinese medicine as toxic herbs to be used with great caution.

3. Key Constituents and Active Compounds

3.1 Alkaloid Classes and Principal Compounds

Over 50 complex steroidal Veratrum alkaloids have been identified and divided into five classes: veratrines, cevanines, jervanines, solanidines, and cholestanes. The veratrines and cevanines are of considerable toxicologic interest as they are neurotoxins and hypotensive agents that bind to sodium channels, delaying closure and causing cardiotoxic and respiratory effects. The jervanines are most significant for their teratogenic effects; the most notable alkaloids were named cyclopamine and jervine, both potent inducers of the congenital cyclopia known as "monkey-faced lamb disease."

Six of the most well-studied V. californicum alkaloids are cyclopamine (1), veratramine (2), isorubijervine (3), muldamine (4), cycloposine (5), and veratrosine (6). Recent inspection of the ethanolic extract from V. californicum root and rhizome via liquid chromatography–mass spectrometry has detected up to five additional alkaloids proposed to be verazine (7), etioline (8), tetrahydrojervine (9), dihydrojervine (10), and 22-keto-26-aminocholesterol (11).

Two unprecedented cyclopamine analogues have also been isolated from Veratrum californicum: 18-hydroxycyclopamine and 24R-hydroxycyclopamine. These are the first compounds of this class to show modifications on rings D–F. 24R-hydroxycyclopamine has been reported to be more potent than cyclopamine in inhibition of the Hedgehog pathway.

3.2 Cyclopamine: The Primary Bioactive Alkaloid

Cyclopamine (chemical name: 11-deoxojervine) is a naturally occurring steroidal alkaloid. It is a teratogenic component of corn lily (Veratrum californicum), which when consumed during gestation has been demonstrated to induce birth defects, including the development of a single eye (cyclopia) in offspring.

Cyclopamine, the V. californicum-derived steroidal alkaloid, was first isolated in 1965 and later identified as an inhibitor of the protein Smoothened (Smo), which is a critical protein in the Hedgehog signaling pathway. The compound, initially referred to as "alkaloid V," was formally named cyclopamine in 1968 following structural elucidation that identified it as 11-deoxojervine, a steroidal alkaloid closely related to jervine.

3.3 Alkaloid Distribution Within the Plant

Detailed analysis of the alkaloid composition of V. californicum by plant part has been performed, with quantitative analysis of cyclopamine, veratramine, muldamine, and isorubijervine in the leaf, stem, and root/rhizome of the plant. Alkaloid combinations enhance Hedgehog signaling pathway antagonism compared to cyclopamine alone, and significant differences are observed in Hh pathway inhibition between stem and root/rhizome extracts, indicating that additional alkaloids present in these extracts are also capable of inhibiting Hh signaling.

HPLC–MS/MS studies of five Veratrum alkaloids (cevadine, jervine, protoveratrine A, veratramine, and veratridine) across three Veratrum species, including V. californicum, found varying alkaloid concentrations among plant parts and Veratrum species in the μg/g to mg/g range. Protoveratrine A exhibited the highest content, while veratramine concentrations were generally lower.

4. Established Mechanisms of Action

4.1 Hedgehog (Hh) Signaling Pathway Inhibition

The precise mechanism of cyclopamine action remained enigmatic for 30 years, until this steroid alkaloid was found to be the first specific inhibitor of Hedgehog (Hh) signaling and a direct antagonist of the transmembrane receptor Smoothened (SMO).

In mammals, the Hh signaling pathway consists of the secreted ligands Sonic hedgehog (Shh), Desert hedgehog (Dhh), and Indian hedgehog (Ihh); the transmembrane receptor proteins Patched (Ptch1 and Ptch2); the transmembrane signal transducer Smoothened (Smo); and the Gli transcription factors (Gli1, Gli2, Gli3). In the absence of Hh ligands, Ptch1 prevents the translocation of Smo to the primary cilia, thereby inhibiting the nuclear localization of Gli and suppressing transcriptional activity.

Using photoaffinity and fluorescent derivatives, it has been demonstrated that the inhibitory effect of cyclopamine is mediated by direct binding to the heptahelical bundle of Smoothened (Smo). Cyclopamine can also reverse the retention of partially misfolded Smo in the endoplasmic reticulum, presumably through binding-mediated effects on protein conformation. Cyclopamine has a high affinity for Smoothened — and upon binding, inhibits the signal. Even though Shh still binds Patched, Smoothened cannot signal in the presence of cyclopamine and thus the pathway is interrupted.

In vivo, treatment of cyclopamine with dilute hydrochloric acid (0.5%) at 38 °C leads to the formation of veratramine — conditions similar to those of gastric acid. Veratramine is highly toxic, acting through excitation of the central nervous system causing seizures — similarly to serotonin. The mechanism for the formation of veratramine from cyclopamine involves cleavage of the spirocyclic carbon-oxygen bond in the THF ring, which through elimination leads to the formation of a double bond.

4.2 Sodium Channel Modulation (Cardiotoxic and Hypotensive Mechanism)

The principal toxins are steroid alkaloids; some have a modified steroid template, whereas others differ in their esterified acid moieties. These alkaloids act by increasing the permeability of the sodium channels of nerve cells, causing them to fire continuously. Increased stimulation associated with the vagal nerve results in a reflex that causes the triad of responses known as the Bezold–Jarisch reflex: hypotension, bradycardia, and apnoea.

4.3 Teratogenic Mechanisms

The mechanisms of action of Veratrum-induced malformations include inhibited cellular movement during differentiation. Cyclopamine interferes with intercellular signals that regulate cellular identity, patterning, and tissue interactions during embryogenesis and organogenesis. The mechanism of cyclopamine-induced birth defects has been shown to result from inhibition of the Sonic Hedgehog signal transduction pathway (Cooper et al. 1998; Incardona et al. 1998).

5. Scientific Evidence by Area of Use

5.1 Discovery of Cyclopamine and Its Teratogenicity: Animal Research

USDA researchers, including William Binns, initiated studies in 1955, surveying affected grazing ranges at elevations of 6,000 to 10,000 feet and ruling out genetic factors through controlled breeding experiments. By 1957, field observations linked the defects to pregnant ewes consuming Veratrum californicum (corn lily) during early gestation, particularly around days 8 to 17, with peak susceptibility on day 14.

While the discovery of V. californicum teratogenicity solved the mystery of the "monkey-faced" lambs, USDA scientists continued to search for causative natural products. Keeler and Binns sequentially extracted dried plant material with benzene/ammonium hydroxide and ethanol; the ethanol-extractable compounds were fractionated further by alumina chromatography and resulting alkaloid-rich extracts were then administered to pregnant ewes on gestation day 14. Through this animal-based screen, the USDA identified three structurally related alkaloids with teratogenic activities: cyclopamine, jervine, and cycloposine.

Evidence strength: Robust animal experimental data (sheep); well-replicated by multiple USDA research groups over decades. No human teratogenicity studies have been conducted, nor would they be ethically permissible.

5.2 Cancer Research — Hedgehog Pathway Inhibition

Of the 17–45 Veratrum spp., V. californicum alkaloids have been proven to possess favorable medicinal properties associated with inhibition of Hedgehog (Hh) pathway signaling. Aberrant Hh signaling leads to proliferation of over 20 cancers, including basal cell carcinoma, prostate cancer, and colon cancer, among others.

5.2.1 Basal Cell Carcinoma — Drug-Development Lineage

Cyclopamine, the teratogenic steroidal alkaloid isolated from corn lily (Veratrum californicum), has recently gained renewed interest due to its anticancer potential, which has been translated into the FDA approval of three Hedgehog (Hh) pathway inhibiting antitumor drugs. Two functional analogs of cyclopamine have been approved by the FDA: vismodegib in 2012 and sonidegib in 2015.

In January 2012, vismodegib (Erivedge, manufactured by Genentech) became the first selective inhibitor of the Hedgehog signaling pathway to be approved by the US Food and Drug Administration for the treatment of locally advanced and metastatic basal cell carcinoma. Approval was granted primarily on the basis of a nonrandomized parallel cohort phase II study of 99 patients with advanced basal cell carcinoma, with a primary endpoint of objective response rate.

In the pivotal study involving 96 patients, vismodegib shrank tumors or healed lesions in 43% of patients with locally advanced basal cell carcinoma (27 of 63) and in 30% of patients with metastatic basal cell carcinoma (10 of 33). Study participants received 150 mg of vismodegib orally, once daily, until disease progression or unacceptable toxicity.

Important distinction: Vismodegib and sonidegib are synthetic SMO inhibitors structurally informed by cyclopamine's mechanism but are not derived from the plant itself. Vismodegib is structurally unrelated to cyclopamine but is able to bind with high affinity and specificity to SMO, leading to potent suppression of Hedgehog signaling. Cyclopamine itself has not progressed to approved clinical drug status.

5.2.2 Breast Cancer — Preclinical (In Vitro)

In epithelial cancer with aberrant Hedgehog activation, abrogation of Hedgehog signaling by cyclopamine, a naturally occurring Hedgehog-specific small-molecule inhibitor, causes profound inhibition of tumor growth. In studies of cyclopamine, significant potency was displayed in suppressing the proliferation of both estrogen-responsive (MCF-7) and estrogen-independent (MDA-MB-231) human breast cancer cells. Cyclopamine induced a robust G1 cell cycle arrest and elicited notable effects on the expression of cyclin D1 through modulation of the MAPK/ERK signaling pathway. Cyclopamine also inhibited the invasive ability of both breast cancer cell lines by suppressing the expression levels of NF-κB, MMP2, and MMP9 protein.

Cyclopamine blocks Hedgehog signaling by antagonizing Smo function, which induces tumor apoptosis. The combined use of cyclopamine and paclitaxel was reported to induce breast cancer cell apoptosis both in vivo and in vitro.

Evidence strength: In vitro cell line studies and mouse xenograft models only. No human clinical trials of cyclopamine in breast cancer have been reported.

5.2.3 Glioblastoma — Preclinical (In Vitro/In Vivo)

Given the requirement for Hedgehog in non-neoplastic stem cells, investigators studied whether Hedgehog blockade could target the stem-like population in glioblastoma multiforme (GBM). Gli1, a key Hedgehog pathway target, was highly expressed in 5 of 19 primary GBM and in 4 of 7 GBM cell lines. Shh ligand was expressed in some primary tumors and in GBM-derived neurospheres, suggesting a potential mechanism for pathway activation. Hedgehog pathway blockade by cyclopamine caused a 40%–60% reduction in growth of adherent glioma lines highly expressing Gli1 but not in those lacking evidence of pathway activity.

Evidence strength: Preclinical (cell lines and primary tumor samples) only. No human clinical evidence.

5.2.4 Prostate Cancer — Preclinical

Studies in preclinical models of rodent and human prostate cancer have confirmed that blockade of Hh signaling by cyclopamine can inhibit tumor growth as well as tumor progression. Administration of cyclopamine causes both down-regulation of proliferation and initiation of apoptosis. This compound, however, has the potential for causing serious side effects in non-tumor tissues. To minimize bystander toxicities, researchers have designed two novel peptide-cyclopamine conjugates as prostate-specific antigen (PSA)-activated prodrugs, composed of cyclopamine coupled to one of two peptides (either HSSKLQ or SSKYQ) that can be selectively cleaved by PSA, converting the mature prodrug into an active Hedgehog inhibitor within the malignant cells.

Evidence strength: Preclinical (rodent and human cell models). No completed human clinical trials of cyclopamine itself in prostate cancer.

5.2.5 Lung Cancer — Preclinical

Aberrant Hedgehog (Hh) signaling is associated with the development of many cancers including prostate cancer, gastrointestinal cancer, lung cancer, pancreatic cancer, ovarian cancer, and basal cell carcinoma. The Hh signaling pathway has been one of the most intensely investigated targets for cancer therapy, and a number of compounds inhibiting Hh signaling are being tested clinically for treating many cancers. Cyclopamine was the first compound found to inhibit Hh signaling and has been invaluable for understanding the function of Hh signaling in development and cancer.

Evidence strength: Preclinical only for cyclopamine in lung cancer. Hh pathway inhibitors more broadly are in clinical development for various indications.

5.2.6 General Limitations of Cyclopamine as a Drug Candidate

While cyclopamine has been demonstrated to inhibit tumor growth in mouse xenograft models, it never reached therapeutic potential as it caused many side effects including weight loss, dehydration, and death in mouse models. Cyclopamine is not water-soluble, which creates problems in drug delivery. Veratrum plant material has been utilized for centuries as herbal medicines; however, the alkaloids have such a low therapeutic index that they are not used in modern medicine.

5.3 Cardiovascular Effects — Historical Clinical Evidence

It was shown that Veratrum compounds do induce in humans a marked decrease in cardiac output coupled with a moderate fall in arterial resistance (Hoobler et al., 1955). The action of two pure veratrum alkaloids, veratridine and protoveratrine, in human hypertension was described, with the vasodepressor reflex pathway reviewed. Protoveratrine was found to produce a striking fall in blood pressure in both essential and renal hypertension after intravenous administration.

Clinically, various Veratrum extracts were marketed for clinical use as antihypertensive drugs, but because of their narrow therapeutic index were withdrawn from the market. Phytotherapies incorporating V. album alkaloids were discontinued due to difficulty in achieving the appropriate dosing for patients; the difference between toxic and therapeutic doses was about 30%.

Evidence strength: Historical human use documented in the mid-20th century clinical literature; subsequently abandoned due to an unacceptably narrow therapeutic index. No modern clinical development is ongoing for this indication using crude plant extracts or cyclopamine.

5.4 Antiparasitic and Dermatological Uses — Traditional with Some Historical Application

In Russia, Veratrum poisonings are more common since there is an over-the-counter Veratrum lobelianum-based tincture, Veratrum Aqua, which is topically used for the treatment of lice infestation. Despite its toxicity, this preparation is misused in traditional medicine as a remedy for alcohol use disorder.

Evidence strength: Largely traditional and ethnopharmacological; no controlled clinical trials in these areas for V. californicum specifically.

6. Body Systems and Health Areas of Association

Oncology / Cellular signaling: V. californicum alkaloids possess favorable medicinal properties associated with inhibition of Hedgehog (Hh) pathway signaling; aberrant Hh signaling leads to proliferation of over 20 cancers, including basal cell carcinoma, prostate, and colon cancer, among others.
Cardiovascular system: Veratrum alkaloids increase the permeability of neuronal sodium channels, causing them to fire continuously; increased stimulation of the vagal nerve results in the Bezold–Jarisch reflex, causing hypotension, bradycardia, and apnea.
Reproductive system / Teratology: Cyclopamine is responsible for a number of congenital defects in lambs, depending on the stage of gestation at which they are consumed. Exposure during the first 10 days of gestation is associated with early embryonic death.
Musculoskeletal system: Exposure to V. californicum between gestation days 25 and 36 results in hypoplasia of the metacarpals and metatarsals in sheep.
Neurological system: Treatment of cyclopamine with conditions similar to those of gastric acid leads to the formation of veratramine, which is highly toxic, acting through excitation of the central nervous system causing seizures — similarly to serotonin.
Integumentary system / Dermatology: Historically associated with topical use for parasitic infections (lice, scabies) and skin conditions including eczema and psoriasis, primarily in European Veratrum species traditions.
Gastrointestinal system: Following the ingestion of Veratrum alkaloids, expected signs and symptoms include vomiting and abdominal pain.

7. Dosage Forms and Reported Dosages

No safe or effective human dosage for Veratrum californicum or any of its isolated alkaloids has been established in the scientific literature for supplemental or therapeutic use. The following represent dosages reported in research contexts only:

In vitro Hh inhibition studies: Treatment conditions evaluating Hh signaling inhibition in Shh-Light II cells used extracts and alkaloid standard mixtures normalized to cyclopamine concentrations of 0.5 µM and 0.1 µM, referred to as "high concentration" and "low concentration."
Vismodegib pivotal clinical trial (the FDA-approved SMO inhibitor derived from the mechanism of cyclopamine): Study participants received 150 mg of vismodegib orally, once daily, until disease progression or unacceptable toxicity.
Historical antihypertensive use: The difference between toxic and therapeutic doses of V. album alkaloids was approximately 30% — indicating an extremely narrow therapeutic window that precluded safe clinical use.
Livestock toxicity threshold: Poisoning in animals may occur within as little as two hours after ingestion, and the threshold for poisoning can be as low as 150 grams of plant material ingested.

Veratrum plant material has been utilized for centuries as herbal medicines; however, the alkaloids have such a low therapeutic index that they are not used in modern medicine.

8. Safety Considerations and Interactions

8.1 Acute Toxicity in Humans

Following the ingestion of Veratrum alkaloids, expected signs and symptoms include vomiting and abdominal pain, followed by cardiovascular effects such as bradycardia, hypotension, and cardiac conduction abnormalities, and death. The onset of symptoms occurs between 30 minutes and 4 hours, and the duration of the illness can range from 1 to 10 days; however, with prompt supportive care, patients typically make a full recovery within 24 hours.

Treatment consists of supportive care, with an emphasis on hemodynamic stability with fluid replacement, atropine, and vasopressors.

Although many cases of Veratrum ingestion have been reported in the Eastern United States and Europe, no case report of human toxicity specifically from Veratrum californicum existed in the literature at the time of a case report published by Seale et al. (PubMed citation: 36301078). In that reported case of known V. californicum ingestion, the patient became hypotensive and bradycardic, requiring fluid resuscitation.

8.2 Whole-Plant Toxicity

All parts of the plant are poisonous to eat. All parts of the plants are toxic, but the roots are 5–10 times more toxic than leaves. Poisoned animals exhibit symptoms such as excessive salivation, problems walking, vomiting, irregular heartbeat, shallow breathing, and convulsions.

8.3 Teratogenic Risk

The classic demonstrable conditions associated with V. californicum ingestion — severe facial abnormalities such as a cyclops-like appearance, anophthalmos, and cleft palate — result when exposure takes place between days 12 and 14 of gestation in sheep. The teratogenic effects of jervine and cyclopamine are due to their specific inhibition of vertebrate cellular responses to the Hedgehog (Hh) family of secreted growth factors. The teratogenic potential of cyclopamine in humans is strongly implied by its mechanism of action and is reproduced in SMO inhibitor drugs: vismodegib carries a boxed warning about a potential risk of death or severe birth defects to a fetus.

8.4 Metabolic Conversion and CNS Risk

Treatment of cyclopamine with conditions similar to those of gastric acid leads to the formation of veratramine. Veratramine is highly toxic, acting through excitation of the central nervous system causing seizures. This in-vivo conversion pathway raises particular concern regarding oral ingestion of any preparation containing cyclopamine.

8.5 Potential Interaction with Immunotherapy

Many Hh inhibitors are undergoing clinical trial and show promise as anticancer drugs. However, Hh signaling is also induced in the activated T and NK (TNK) lymphocytes that are used in immunotherapy. This suggests a theoretical basis for interference between Hh inhibitors derived from V. californicum and immune-based cancer therapies, though direct clinical interaction data are not available.

8.6 Narrow Therapeutic Index

Clinically, various Veratrum extracts were marketed for clinical use as antihypertensive drugs, but because of their narrow therapeutic index were withdrawn from the market. Much of our understanding of Veratrum spp. component activity originates from animal or human poisoning associated with accidental ingestion of plant material. Observations of one-eyed sheep birth defects, low heart rate, vomiting, diarrhea, and other side effects attributable to Veratrum poisoning have led to investigations identifying active constituents.

9. Summary of Evidence Strength

The scientific literature on Veratrum californicum is substantial but almost entirely preclinical. Cyclopamine's role as the founding member of a new class of cancer drug target (SMO inhibitors) is historically significant and well-documented. However, cyclopamine itself has never been approved for human therapeutic use. Its direct clinical legacy is embodied in FDA-approved synthetic SMO inhibitors (vismodegib and sonidegib), which are structurally related but distinct molecules. For V. californicum as a dietary supplement or herbal preparation, there are no human clinical trials, no established safe dosage, no regulatory approval in any major jurisdiction, and documented severe toxicity at relatively low exposures.

References

Health Conditions

Health conditions that California false hellebore may help support.

No conditions available.

Body Systems

Body systems that California false hellebore may help support.

No body systems available.